Use of drug therapy in the management of symptomatic ureteric stones in hospitalized adults (SUSPEND), a multicentre, placebo-controlled, randomized trial of a calcium-channel blocker (nifedipine) and an α-blocker (tamsulosin): Study protocol for a randomized controlled trial

Trials

Volumn 15, Issue 1, 2014, Pages

  McClinton, Sam ^a,b   Starr, Kathryn ^b,c   Thomas, Ruth ^c   McLennan, Graeme ^c   McPherson, Gladys ^c   McDonald, Alison ^c   Lam, Thomas ^a,b   N'Dow, James ^a,b   Kilonzo, Mary ^b   Pickard, Robert ^d   Anson, Ken ^e   Burr, Jennifer ^f   Burgess, Neil ^g   Preminger, Glen ^g   Patel, Uday ^g   McMullan, Kathryn ^g   Norrie, John ^g   MacLennan, Graeme ^g   Schumm, Katie ^g   Wright, Patrick ^g   Clark, Terry ^g   more..

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e ST GEORGE S HOSPITAL   (United Kingdom)

^f UNIVERSITY OF ST ANDREWS   (United Kingdom)

^g Department of Medical and Biological Sciences University of St Andrews ^*

Author keywords

medical expulsive therapy; nifedipine; tamsulosin; ureteric stone

Indexed keywords

NIFEDIPINE; PETYME; PLACEBO; TAMSULOSIN; UNCLASSIFIED DRUG; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; MUSCLE RELAXANT AGENT; SULFONAMIDE;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; HOSPITAL PATIENT; HUMAN; INTENTION TO TREAT ANALYSIS; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PHARMACEUTICAL CARE; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URETER STONE; ADOLESCENT; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFECTS; ECONOMICS; GREAT BRITAIN; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; MUSCLE RELAXATION; PATHOPHYSIOLOGY; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; SMOOTH MUSCLE; TIME FACTOR; URETER; URETERAL CALCULI; YOUNG ADULT;

ADOLESCENT; ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ADULT; AGED; CALCIUM CHANNEL BLOCKERS; CLINICAL PROTOCOLS; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; DRUG COSTS; FEMALE; GREAT BRITAIN; HUMANS; INPATIENTS; MALE; MIDDLE AGED; MUSCLE RELAXATION; MUSCLE, SMOOTH; NEUROMUSCULAR AGENTS; NIFEDIPINE; RESEARCH DESIGN; SULFONAMIDES; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; URETER; URETERAL CALCULI; YOUNG ADULT;

EID: 84902707147     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-15-238     Document Type: Article

References (28)

1. Menon M, Resnick MI. Urinary lithiasis: etiology, diagnosis, and medical and management. Campbell's Urology 2002, 3229. Philadelphia: WB Saunders Co, Walsh PC, Retik AB, Vaughan EDJr, Wein AJ, 8.
2. Wilkinson H. Clinical investigation and management of patients with renal stones. Ann Clin Biochem 2001, 38:180-187. 10.1258/0004563011900623, 11392494.
3. Bihl G, Meyers A. Recurrent renal stone disease-advances in pathogenesis and clinical management. Lancet 2001, 358:651-656. 10.1016/S0140-6736(01)05782-8, 11530173.
4. Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int 2003, 63:1817-1823. 10.1046/j.1523-1755.2003.00917.x, 12675858.
5. Hospital Episode Statistics (HES) Online. http://www.hscic.gov.uk/hes.
6. Preminger GM, Tiselius HG, Assimos DG, Alken P, Buck AC, Gallucci M, Knoll T, Lingeman JE, Nakada SY, Pearle MS, Sarica K, Türk C, Wolf JS, . American Urological Association Education and Research, Inc, European Association of Urology 2007 guideline for the management of ureteral calculi. Eur Urol 2007, 2007(52):1610-1631. American Urological Association Education and Research, Inc, European Association of Urology.
7. Obara K, Takeda M, Shimura H, Kanai T, Tsutsui T, Komeyama T. Alpha-1 adrenoreceptor subtypes in the human ureter: characterization by RT-PCR and in situ hybridization. J Urol 1996, 155(suppl 5):472A. abstract 646.
8. Sigala S, Dellabella M, Milanese G, Fornari S, Faccoli S, Palazzolo F, Peroni A, Mirabella G, Cunico SC, Spano P, Muzzonigro G. Evidence for the presence of α1 adrenoceptor subtypes in the human ureter. Neurourol Urodyn 2005, 24:142-148. 10.1002/nau.20097, 15690361.
9. Itoh Y, Kojima Y, Yasui T, Tozawa K, Sasaki S, Kohri K. Examination of alpha 1 adrenoceptor subtypes in the human ureter. Int J Urol 2007, 14:749-753. 10.1111/j.1442-2042.2007.01812.x, 17681068.
10. Richardson CD, Donatucci CF, Page SO, Wilson KH, Schwinn DA. Pharmacology of tamsulosin: saturation-binding isotherms and competition analysis using cloned α1-adrenergic receptor subtypes. Prostate 1997, 33:55-59. 10.1002/(SICI)1097-0045(19970915)33:1<55::AID-PROS9>3.0.CO;2-8, 9294627.
11. Noble AJ, Chess-Williams R, Couldwell C, Furukawa K, Uchyiuma T, Korstanje C, Chapple CR. The effects of tamsulosin, a high affinity antagonist at functional α1A- and α1D-adrenoceptor subtypes. Br J Pharmacol 1997, 120:231-238. 10.1038/sj.bjp.0700907, 1564378, 9117115.
12. Elliott HL, Meredith PA, Sumner DJ, McLean K, Reid JL. A pharmacodynamic and pharmacokinetic assessment of a new alpha-adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects. Br J Clin Pharmacol 1982, 13:699-703. 10.1111/j.1365-2125.1982.tb01439.x, 1402070, 6123342.
13. Lepor H, Gup DI, Baumann M, Shapiro E. Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia. Urology 1988, 32(6 Suppl):21-26.
14. Lefèvre-Borg F, O'Connor SE, Schoemaker H, Hicks PE, Lechaire J, Gautier E, Pierre F, Pimoule C, Manoury P, Langer SZ. Alfuzosin, a selective alpha 1-adrenoceptor antagonist in the lower urinary tract. Br J Pharmacol 1993, 109:1282-1289. 10.1111/j.1476-5381.1993.tb13762.x, 2175718, 8104650.
15. Hertle L, Nawrath H. Calcium channel blockade in smooth muscle of the human upper urinary tract. I. Effects on depolarization-induced activation. J Urol 1984, 132:1265-1269.
16. Salman S, Castilla C, Vela Navarrete R. Action of calcium antagonists on ureteral dynamics. Actas Urol Esp 1989, 13:150-152.
17. Hollingsworth JM, Rogers MA, Kaufman SR, Bradford TJ, Saint S, Wei JT, Hollenbeck BK. Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet 2006, 368:1171-1179. 10.1016/S0140-6736(06)69474-9, 17011944.
18. Singh A, Alter HJ, Littlepage A. A systematic review of medical therapy to facilitate passage of ureteral calculi. Ann Emerg Med 2007, 50:552-563. 10.1016/j.annemergmed.2007.05.015, 17681643.
19. Vincendeau S, Bellissant E, Bensalah K, Houlgatte A, Doré B, Bruyere F, Patard J, Guillé F. Lack of efficacy of tamsulosin in the treatment of distal ureteral stones. Eur Urol Suppl 2008, 7(3):149.
20. Bensalah K, Pearle M, Lotan Y. Cost-effectiveness of medical expulsive therapy using alpha-blockers for the treatment of distal ureteral stones. Eur Urol 2008, 53:411-418. 10.1016/j.eururo.2007.09.012, 17889988.
21. EudraLex The Rule Governing Medicinal Products in the EU: Good Manufacturing Practices. Volume 4, Annex 13 2010, Brussels: European Commission, http://ec.europa.eu/health/documents/eudralex/vol-4/index_en.htm, EudraLex.
22. Keele KD. The pain chart. Lancet 1948, 252(6514):6-8.
23. Downie WW, Leathem PA, Rhind PA. Studies with pain rating scales. Ann Rheum Dis 1978, 37:378-381. 10.1136/ard.37.4.378, 1000250, 686873.
24. Schulz K, Grimes D. Multiplicity in randomised trials I: endpoints and treatments. Lancet 2005, 365:1591-1595. 10.1016/S0140-6736(05)66461-6, 15866314.
25. Department for Health NHS Pay Review Body, Twenty-Sixth Report 2012. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/228908/8298.pdf, Department for Health.
26. Value of time and operating costs: transport analysis guidance (TAG). http://www.dft.gov.uk/webtag/documents/archive/1208/unit3.5.6.pdf.
27. Office for National Statistics Statistical Bulletin Annual Survey of Hours and Earnings, 2013 Provisional Results. http://www.ons.gov.uk/ons/dcp171778_335027.pdf, Office for National Statistics Statistical Bulletin.
28. Kind P, Hardman G, Macran S. UK population norms for EQ-5D. Centre for Health Economics Discussion Paper 172 1999, York: University of York.